Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Incesu, RB; Barletta, F; Tappero, S; Piccinelli, ML; Garcia, CC; Morra, S; Scheipner, L; Tian, Z; Saad, F; Shariat, SF; Ahyai, S; Longo, N; Chun, FKH; de, Cobelli, O; Terrone, C; Briganti, A; Tilki, D; Graefen, M; Karakiewicz, PI.
Survival differences in non-seminoma testis cancer patients according to race/ethnicity.
Cancer Epidemiol. 2024; 89:102538
Doi: 10.1016/j.canep.2024.102538
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Ahyai Sascha
- Scheipner Lukas
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: Historic evidence suggests that non-Caucasian race/ethnicity predisposes to higher testis cancer-specific mortality (CSM) in non-seminoma. However, it is unknown, whether higher CSM in non-Caucasians applies to Hispanics or Asians or African-Americans, or all of the above groups. In contemporary patients, we tested whether CSM is higher in these select non-Caucasian groups than in Caucasians, in overall and in stage-specific comparisons: stage I vs. stage II vs. stage III. METHODS: The Surveillance, Epidemiology, and End Results (SEER) database (2004 -2019) was used. Kaplan-Meier plots and multivariable Cox regression models tested the effect of race/ethnicity on CSM after stratification for stage (I vs. II vs. III) and adjustment for prognosis groups in stage III. RESULTS: In all 13,515 non-seminoma patients, CSM in non-Caucasians was invariably higher than in Caucasians. In stage-specific analyses, race/ethnicity represented an independent predictor of CSM in Hispanics in stage I (HR 1.8, p = 0.004), stage II (HR 2.2, p = 0.007) and stage III (HR 1.4, p < 0.001); in African-Americans in stage I (HR 3.2; p = 0.007) and stage III (HR 1.5; p = 0.042); and in Asians in only stage III (HR 1.6, p = 0.01). CONCLUSIONS: In general, CSM is higher in non-Caucasian non-seminoma patients. However, the CSM increase differs according to non-Caucasian race/ethnicity groups. Specifically, higher CSM applies to all stages of non-seminoma in Hispanics, to stages I and III in African-Americans and only to stage III in Asians. These differences are important for individual patient management, as well as for design of prospective trials.
- Find related publications in this database (using NLM MeSH Indexing)
- Humans - administration & dosage
- Male - administration & dosage
- Ethnicity - administration & dosage
- Proportional Hazards Models - administration & dosage
- Prospective Studies - administration & dosage
- SEER Program - administration & dosage
- Testicular Neoplasms - administration & dosage
- White - administration & dosage
- Survival - administration & dosage
- Racial Groups - administration & dosage
- Healthcare Disparities - administration & dosage
- Find related publications in this database (Keywords)
- Testis cancer
- Non-seminoma
- Survival
- Race/ethnicity
- IGCCCG